# Disclosure according to Article 5 Section (1) and (6) of the EU Regulation 596/2014 in conjunction with Article 2 Section (2) and (3) of the Delegated EU Regulation 2016/1052 / Share Repurchase - Interim Reporting 

With disclosure dated May 15, 2018, QIAGEN N.V. announced pursuant to Article 5 Section (1) and (6) of the EU Regulation no 596/2014 and Article 2 Section (1) of the Delegated EU Regulation no 2016/1052 the immediate beginning of a first tranche of up to USD 50 million under the share repurchase program originally announced on January 31, 2018.

The number of shares which have been bought back on the electronic trading platform of the Frankfurt Stock Exchange (XETRA) within the framework of such tranche of the share repurchase program in the time period from August 06, 2018 until and including August 10, 2018 amounts to 58,421 shares.

Shares were bought back as follows:

| Date | Number of Shares <br> acquired | Average Price (EUR) | Purchased Volume <br> (EUR) |
| :---: | :---: | :---: | :---: |
| 06-August-2018 | 11,707 | 33.3968 | $390,976.34$ |
| 07-August-2018 | 11,594 | 33.7240 | $390,996.06$ |
| 08-August-2018 | 11,618 | 33.6527 | $390,977.07$ |
| 09-August-2018 | 11,764 | 33.2356 | $390,983.60$ |
| 10-August-2018 | 11,738 | 33.3104 | $390,997.48$ |
| Total | 58,421 | $\mathbf{3 3 . 4 6 2 8}$ | $\mathbf{1 , 9 5 4 , 9 3 0 . 5 4}$ |

The underlying individual trades are published on the website of QIAGEN N.V. (http://corporate.qiagen.com/investor-relations/share-information/share-buyback).

The total number of shares which have already been bought back within the framework of such tranche of the share repurchase program from May 15, 2018 until and including August 10, 2018 amounts to $1,261,661$ shares.

The purchase of the shares of QIAGEN N.V. was carried out by a financial institution that has been commissioned by QIAGEN N.V.

Venlo, 14 August 2018
Managing Board

|  | \#\#\# |  |  |
| :---: | :---: | :---: | :---: |
| Contacts: |  |  |  |
| QIAGEN |  |  |  |
| Investor Relations |  | Public Relations |  |
| John Gilardi | +49 21032911711 | Dr. Thomas Theuringer | +49 21032911826 |
| e-mail: ir@qiagen.com |  | e-mail: pr@qiagen.com |  |

